Intravenous propofol: unique effectiveness in treating intractable migraine

Area of Science:

• Neurology
• Anesthesiology
• Pharmacology

Background:

• Propofol, an intravenous anesthetic, was observed to provide 100% migraine relief in six patients undergoing nerve block procedures.
• This led to a study investigating subanesthetic doses of propofol for intractable headaches refractory to standard treatments.

Purpose of the Study:

• To evaluate the effectiveness of intravenous propofol in treating refractory migraines and other severe headaches.
• To establish propofol as a potential new abortive treatment option in headache clinics and emergency settings.

Main Methods:

• Seventy-seven patients with intractable migraines and non-migrainous headaches received intravenous propofol treatment.
• The treatment was administered in an outpatient headache clinic setting.

Main Results:

• An average headache intensity reduction of 95.4% was achieved within 20-30 minutes of propofol administration.
• Complete headache abolition was reported by 63 out of 77 patients, with minimal recurrence.
• The average propofol dose was subanesthetic (110 mg), well within preanesthetic ranges.

Conclusions:

• Intravenous propofol demonstrates rapid and highly effective abortive treatment for severe, intractable headaches.
• Propofol offers a promising alternative to existing treatments for acute migraine and other refractory headache conditions.
• The efficacy of propofol prompts further investigation into the neuropharmacology and pathophysiology of migraines.